Metraipolis › archive › dc_0dedb75ea42b

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry — Europe PMC PMID:41442468

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41442468
DOI
10.1093/oncolo/oyaf428
License (as archived)
solo-consultazione
Archived
2026-11-07T05:47:51.268Z
SHA-256 of the archived text
8a4b2bb0bd90304335ba967661a47c99380076f2deafe4375e713d392f648eb0
Stable URL of this page
https://metraipolis.com/documento/dc_0dedb75ea42b

How to cite

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry — Europe PMC PMID:41442468 — Europe PMC (en), https://europepmc.org/article/MED/41442468 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0dedb75ea42b (Metraipolis archive dc_0dedb75ea42b, sha256 8a4b2bb0bd90304335ba967661a47c99380076f2deafe4375e713d392f648eb0)
BibTeX
@misc{dc0dedb75ea42b,
  title = {Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry — Europe PMC PMID:41442468},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41442468},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0dedb75ea42b; sha256 8a4b2bb0bd90304335ba967661a47c99380076f2deafe4375e713d392f648eb0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41442468. Agents can read the archived copy with the MCP tool read_document.